by Nichole Tucker
The DUO-O press release went out on 4/5/2023. It suggests that adding immunotherapy to PARP inhibitor maintenance therapy for newly diagnosed ovarian cancer patients that have finished first-line platinum treatment may be beneficial. We are eagerly awaiting … Read more
by Jessica Nye, PhD
Patients with platinum-resistant epithelial ovarian cancer may have better overall survival (OS) if they enroll on a clinical trial than if they receive standard care, according to study results presented at the 2023 SGO Annual Meeting … Read more
by Devin McLaughlin
Neoadjuvant therapy with olaparib showed feasibility for women with germline-mutant ovarian cancer, according to results of the NOW trial presented at Society of Gynecologic Oncology Annual Meeting on Women’s Cancer.
Researchers observed favorable surgical outcomes — even … Read more
by Jason Harris
Botensilimab (AGEN1181) in combination with balstilimab (AGEN2034) induced durable responses in patients with resistant/refractory ovarian cancer, according to findings from the phase 1 C-800 study (NCT03860272) presented at the 2023 SGO Annual Meeting on Women’s Cancer.1… Read more
By Kristi Rosa
The FDA has granted accelerated approval to mirvetuximab soravtansine-gynx (Elahere) for the treatment of adult patients with folate receptor α (Frα)–positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received 1 to 3 prior … Read more
Barcelona, Spain: Patients with cancers that are driven by certain mutations occurring in response to DNA damage can be safely treated with two drugs, olparib and adavosertib, if they are given in sequence rather than concurrently.
Presenting results from the … Read more
by Ariana Pelosci
A recent study presented at IGCS 2022 looking at clinical trial enrollment found that Black patients experienced the biggest increase in accrual following an NCI call-to-action for more diversity in clinical trials.
A recent single-institution study presented
— A response to “practice-changing data” in the first- and second-line setting
by Mike Bassett
by Kristi Rosa
Maintenance treatment with niraparib produced a sustained and durable progression-free survival benefit in patients with primary advanced ovarian cancer who responded to first-line platinum-based chemotherapy, spanning biomarker subgroups.
Maintenance treatment with niraparib (Zejula) produced a sustained and
by Jordyn Sava
In an interview with Targeted Oncology during the EMSO Annual Congress, David O’Malley, MD, discussed the phase 1 study of ubamatamab in ovarian cancer.
Ubamatamab, a novel MUC16 antibody, demonstrated evidence of durable responses in patients with … Read more
by Victoria Johnson
ADP-A2M4CD8 will be evaluated in the phase 2 SURPASS-3 trial initiating in late 2022 or early 2023.
ADP-A2M4CD8, a CD8+ T-cell receptor (TCR) engineered T-cell therapy has yielded responses across a variety of MAGE-A4+ solid tumors, including
… Read moreby Mike Bassett
— Results from SOLO-1 and PAOLA-1 show “clinically meaningful” long-term results with olaparib
PARIS — Olaparib (Lynparza) maintenance therapy appears to offer a long-term overall survival (OS) benefit for women with ovarian cancer, according to two phase … Read more
by Erin Hunter
Women at high risk for breast and ovarian cancer felt less worried and better informed with educational intervention, even if their attendance of genetic counseling did not significantly increase.
A new study shows that access to clinician
by University of Texas M.D. Anderson Cancer Center
Newswise — CHICAGO ― Results from three early-stage clinical trials led by researchers at The University of Texas MD Anderson Cancer Center show promising activity with novel immunotherapies and targeted therapies for … Read more
by Ariana Pelosci
The ATHENA-MONO trial showed a significant improvement in progression-free survival when patients with platinum-sensitive ovarian cancer were treated with maintenance rucaparib vs placebo in the first-line setting, regardless of HRD status.
Rucaparib (Rubraca) significantly improved progression-free survival
by Caroline Hopkins
CHICAGO – AstraZeneca’s investigational WEE1 inhibitor adavosertib showed potential in biomarker-selected advanced ovarian cancer populations in two studies presented during the American Society of Clinical Oncology’s annual meeting Saturday.
The drug, which AstraZeneca licensed from Merck in … Read more
by Kelly Irvin
It’s good to have all the facts when you decide whether to participate in a cancer drug clinical trial—even the ones that make you swallow hard and tear up.
To find clinical trials, please check out the … Read more
by Ariana Pelosci
An individualized starting dose of niraparib, determined by weight and platelet count continued to demonstrate a clinical meaningful improvement in progression-free survival in newly diagnosed ovarian cancer in the first-line maintenance setting, regardless of biomarker status.
An
by Rachel N. Grisham, M.D.
As summarized in this issue of The ASCO Post, the highly anticipated results of the GOG 281/LOGS study, which randomly assigned patients with recurrent low-grade serous ovarian cancer to the MEK inhibitor trametinib vs … Read more
by Conor Killmurray
Eighty-percent of all patients treated with durvalumab and tremelimumab in combination with neoadjuvant chemotherapy at least had a partial response to treatment prior to the end of a phase 2 trial.
The use of dual immune checkpoint
… Read more
